Richard Day


Affiliation: University of New South Wales
Country: Australia


  1. Milder T, Stocker S, Abdel Shaheed C, McGrath Cadell L, Samocha Bonet D, Greenfield J, et al. Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. J Clin Med. 2019;8: pubmed publisher
    ..High dose SGLT2 inhibitor/metformin combination therapy appears to have modest weight, but no glycaemic benefits compared with the low dose combination therapy. ..
  2. Kumar S, McManus H, Radovich T, Greenfield J, Viardot A, Williams K, et al. Interrogation of a longitudinal, national pharmacy claims dataset to explore factors that predict the need for add-on therapy in older and socioeconomically disadvantaged Australians with type 2 diabetes mellitus patients (T2DM). Eur J Clin Pharmacol. 2018;74:1327-1332 pubmed publisher
    ..Several factors can predict the risk of prescription of add-on therapy, and these should be considered when prescribing medications to treat T2DM. ..
  3. request reprint
    Day R, Williams K. Open-label extension studies: do they provide meaningful information on the safety of new drugs?. Drug Saf. 2007;30:93-105 pubmed
    ..However, this goal is increasingly being achieved by means other than open-label extension studies. ..
  4. request reprint
    Day R, Birkett D, Miners J, Shenfield G, Henry D, Seale J. Access to medicines and high-quality therapeutics: global responsibilities for clinical pharmacology. Med J Aust. 2005;182:322-3 pubmed
    ..A major theme of the 2004 World Congress of Clinical Pharmacology and Therapeutics was worldwide equity of access to medicines. ..
  5. Ghosh D, Williams K, Graham G, Nair P, Buscher H, Day R. Multiple episodes of aspirin overdose in an individual patient: a case report. J Med Case Rep. 2014;8:374 pubmed publisher
    ..Our experience in this case also revealed considerable unexplained variation in management despite the availability of guidelines. It is, therefore, important to monitor the implementation of available guidelines. ..
  6. request reprint
    Day R, Roffe D, Richardson K, Baysari M, Brennan N, Beveridge S, et al. Implementing electronic medication management at an Australian teaching hospital. Med J Aust. 2011;195:498-502 pubmed
  7. Duong J, Furlong T, Roberts D, Graham G, Greenfield J, Williams K, et al. The Role of Metformin in Metformin-Associated Lactic Acidosis (MALA): Case Series and Formulation of a Model of Pathogenesis. Drug Saf. 2013;36:733-46 pubmed publisher
    ..In this condition, dosage with metformin should be stopped and patients should receive urgent medical attention. ..
  8. McKinney C, Stamp L, Dalbeth N, Topless R, Day R, Kannangara D, et al. Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout. Arthritis Res Ther. 2015;17:288 pubmed publisher
  9. Vaccher S, Kannangara D, Baysari M, Reath J, Zwar N, Williams K, et al. Barriers to Care in Gout: From Prescriber to Patient. J Rheumatol. 2016;43:144-9 pubmed publisher
    ..Also, given the prevalence, and personal and societal significance of gout, innovative approaches to transforming the management of this eminently treatable disease are needed. ..

More Information


  1. Mathieson S, Billot L, Maher C, McLachlan A, Latimer J, Koes B, et al. PRECISE--pregabalin in addition to usual care: statistical analysis plan. Trials. 2016;17:53 pubmed publisher
    ..Australian and New Zealand Clinical Trials Registry (ACTRN12613000530729. Registered 13 May 2013). ..
  2. request reprint
    Moon J, Kumar S, Graham G, Baysari M, Williams K, Chen W, et al. Trends in metformin utilisation and dose appropriateness in Australia. Eur J Clin Pharmacol. 2016;72:1489-1496 pubmed
    ..Metformin may be used safely when renal function is poor provided dosage is appropriately reduced. ..
  3. request reprint
    Day R, Kamel B, Kannangara D, Williams K, Graham G. Xanthine oxidoreductase and its inhibitors: relevance for gout. Clin Sci (Lond). 2016;130:2167-2180 pubmed
  4. Kannangara D, Ramasamy S, Indraratna P, Stocker S, Graham G, Jones G, et al. Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients. Arthritis Res Ther. 2012;14:R189 pubmed publisher
    ..Spot-FCU determinations may provide useful correlates in studies investigating molecular mechanisms underpinning the observed range of efficiencies of the kidneys in clearing urate from the blood. ACTRN12611000743965. ..
  5. Nguyen A, Baysari M, Kannangara D, Tariq A, Lau A, Westbrook J, et al. Mobile applications to enhance self-management of gout. Int J Med Inform. 2016;94:67-74 pubmed publisher
  6. Kamel B, Graham G, Williams K, Pile K, Day R. Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet. 2017;56:459-475 pubmed publisher
    ..The percentage reduction in the concentrations of serum urate is slightly less in gouty patients than in healthy subjects. ..